AngioDynamics, Inc. (ANGO)

US — Healthcare Sector

Peers: NSTG ATRI ATR KRMD ATRC AKYA ICUI HAE MMSI NVST COO

Automate Your Wheel Strategy on ANGO

With Tiblio's Option Bot, you can configure your own wheel strategy including ANGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol ANGO
Rev/Share 6.9351
Book/Share 4.5497
PB 2.1342
Debt/Equity 0.0269
CurrentRatio 2.2094
ROIC -0.1179

MktCap 394293970.0
FreeCF/Share -0.8128
PFCF -11.8742
PE -9.5836
Debt/Assets 0.0175
DivYield 0
ROE -0.2137

Rating
Score
Recommendation
P/E Score
DCF Score
P/B Score
D/E Score

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?

ANGO
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

image for news Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?

Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

ANGO
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

image for news Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet

ANGO
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

image for news Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet

AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands

ANGO
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive

ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.

image for news AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

ANGO
Published: April 02, 2025 by: Benzinga
Sentiment: Positive

AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.

image for news Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

About AngioDynamics, Inc. (ANGO)

IPO Date 2004-06-01
Website https://www.angiodynamics.com
Industry Medical - Instruments & Supplies
CEO Mr. James C. Clemmer
Employees 748

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.